GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bausch Health Companies Inc (TSX:BHC) » Definitions » Debt-to-Revenue

Bausch Health (TSX:BHC) Debt-to-Revenue : 2.14 (As of Sep. 2024)


View and export this data going back to 1987. Start your Free Trial

What is Bausch Health Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Bausch Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was C$614 Mil. Bausch Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was C$28,520 Mil. Bausch Health's annualized Revenue for the quarter that ended in Sep. 2024 was C$13,600 Mil. Bausch Health's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 2.14.


Bausch Health Debt-to-Revenue Historical Data

The historical data trend for Bausch Health's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch Health Debt-to-Revenue Chart

Bausch Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.01 2.98 2.69 2.56 2.56

Bausch Health Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.51 2.32 2.56 2.25 2.14

Competitive Comparison of Bausch Health's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bausch Health's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bausch Health's Debt-to-Revenue falls into.



Bausch Health Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Bausch Health's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(603.72 + 29432.021) / 11748.391
=2.56

Bausch Health's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(613.634 + 28519.748) / 13600.184
=2.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Bausch Health Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bausch Health's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bausch Health Business Description

Traded in Other Exchanges
Address
2150 Saint Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Executives
Seana Lynne Carson Senior Officer
Robert Allen Spurr Senior Officer
Joseph Gordon Senior Officer
Steven Daniel Miller Director
Andrew Charles Von Eschenbach Director
Richard Urbain De Schutter Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Osama Eldessouky Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Amy Wechsler Director
William Douglas Humphries Senior Officer
John Paulson Director
Thomas Ross Sr. Director
Christina Ackermann Senior Officer
Joseph Papa Director, Senior Officer
Paul Herendeen Senior Officer